Previous 10 | Next 10 |
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 1.6% to $12 on volume of 162,538,711 shares Safe & Green Holdings Corp. (SGBX) rose 52.0% to $0.219 on volume of 135,670,644 shares Tesla Inc. (TSLA) rose 5.0% to $170.18 on volume of 124,333,134 shares...
2024-04-25 15:56:49 ET Summary Bristol-Myers Squibb's Q1 2024 earnings release today has resulted in a drop in its share price in trading today. BMY's market cap valuation is lower than competitors such as Vertex and Regeneron, despite substantially higher revenues and net earning...
2024-04-25 13:11:06 ET Bristol-Myer Squibb Company (BMY) Q1 2024 Earnings Conference Call April 25, 2024, 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executi...
2024-04-25 13:05:01 ET The pharmaceutical company's financials show steady revenue growth and improved net income margin in 2024. Management focuses on diversifying the portfolio, advancing drug development, and mitigating risks. Key performance indicators include revenue, expenses, assets, a...
2024-04-25 11:57:34 ET Shares of Bristol Myers Squibb (NYSE: BMY) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its first-quarter results before the market opened. Bristol Myers Squibb reported Q1 revenue of $11.9 billion, up...
2024-04-25 11:30:11 ET Image source: The Motley Fool. Bristol Myers Squibb (NYSE: BMY) Q1 2024 Earnings Call Apr 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transc...
2024-04-25 10:45:00 ET Many top healthcare stocks provide investors with long-term stability, promising growth prospects, and in some cases even a dividend. Yet, investors don't appear to be sold on the fact that Bristol Myers Squibb (NYSE: BMY) checks off all those boxes. The b...
2024-04-25 10:08:18 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...